PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation N Patsoukis, K Bardhan, P Chatterjee, D Sari, B Liu, LN Bell, ED Karoly, ... Nature communications 6 (1), 6692, 2015 | 1109 | 2015 |
The PD1: PD-L1/2 pathway from discovery to clinical implementation K Bardhan, T Anagnostou, VA Boussiotis Frontiers in immunology 7, 550, 2016 | 596 | 2016 |
Epigenetics and colorectal cancer pathogenesis K Bardhan, K Liu Cancers 5 (2), 676-713, 2013 | 323 | 2013 |
NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression F Liu, K Bardhan, D Yang, M Thangaraju, V Ganapathy, JL Waller, ... Journal of Biological Chemistry 287 (30), 25530-25540, 2012 | 179 | 2012 |
Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo D Yang, CM Torres, K Bardhan, M Zimmerman, TL McGaha, K Liu The Journal of Immunology 188 (9), 4441-4449, 2012 | 107 | 2012 |
Corrigendum: Regulation of T Cell Differentiation and Function by EZH2 BVA Karantanos T, Christofides A, Bardhan K, Li L front immunol 7, 172, 2016 | 99 | 2016 |
Clinical significance of T cell metabolic reprogramming in cancer C Herbel, N Patsoukis, K Bardhan, P Seth, JD Weaver, VA Boussiotis Clinical and translational medicine 5, 1-23, 2016 | 95 | 2016 |
GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology H Liu, L Huang, J Bradley, K Liu, K Bardhan, D Ron, AL Mellor, DH Munn, ... Molecular and cellular biology 34 (3), 428-438, 2014 | 87 | 2014 |
Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer X Hu, K Bardhan, AV Paschall, D Yang, JL Waller, MA Park, ... Journal of Biological Chemistry 288 (26), 19103-19115, 2013 | 78 | 2013 |
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. BVA Christofides A, Karantanos T, Bardhan K oncotarget, 2016 | 60 | 2016 |
Acquired resistance of EGFR-mutated lung cancer to tyrosine kinase inhibitor treatment promotes PARP inhibitor sensitivity L Marcar, K Bardhan, L Gheorghiu, P Dinkelborg, H Pfäffle, Q Liu, ... Cell reports 27 (12), 3422-3432. e4, 2019 | 59 | 2019 |
IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation AV Paschall, R Zhang, CF Qi, K Bardhan, L Peng, G Lu, J Yang, M Merad, ... The Journal of Immunology 194 (5), 2369-2379, 2015 | 56 | 2015 |
IFNγ induces DNA methylation–silenced GPR109A expression via pSTAT1/p300 and H3K18 acetylation in colon cancer K Bardhan, AV Paschall, D Yang, MR Chen, PS Simon, YD Bhutia, ... Cancer immunology research 3 (7), 795-805, 2015 | 45 | 2015 |
The role of metabolic reprogramming in T cell fate and function N Patsoukis, K Bardhan, J Weaver, C Herbel, P Seth, L Li, VA Boussiotis Current trends in immunology 17, 1, 2016 | 44 | 2016 |
Lymphotoxin β receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of … X Hu, MA Zimmerman, K Bardhan, D Yang, JL Waller, GB Liles, JR Lee, ... Carcinogenesis 34 (5), 1105-1114, 2013 | 40 | 2013 |
The PD‐1 Interactome Q Wang, K Bardhan, VA Boussiotis, N Patsoukis Advanced biology 5 (9), 2100758, 2021 | 33 | 2021 |
Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells K Bardhan, HI Aksoylar, T Le Bourgeois, L Strauss, JD Weaver, B Delcuze, ... Scientific reports 9 (1), 17252, 2019 | 32 | 2019 |
The PD1: PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016; 7: 550 K Bardhan, T Anagnostou, VA Boussiotis Epub 2016/12/27. https://doi. org/10.3389/fimmu. 2016.00550 PMID: 28018338, 2016 | 31 | 2016 |
The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression N Patsoukis, K Bardhan, JD Weaver, D Sari, A Torres-Gomez, L Li, ... Science signaling 10 (493), eaam8298, 2017 | 30 | 2017 |
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 6: 6692 N Patsoukis, K Bardhan, P Chatterjee, D Sari, B Liu, LN Bell, ED Karoly, ... Immunity 38, 633-643, 2015 | 28 | 2015 |